It’s no exaggeration that calcium represents the Achilles heel of endovascular treatment. As the patient population continues to evolve in complexity we need solutions that can treat severe calcified disease in an efficacious, safe and durable way. Listen as Dr Konstantinos Stavroulakis shares the outcomes of his recent publication of Intravascular Lithotripsy (IVL) and DCB in severely calcified femoropopliteal lesions followed out to 12 months and understand why he believes IVL is a game changer in the treatment of complex real world patients.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
In a few weeks, we are headed to a city known for its sunshine and southern hospitality, Atlanta, Georgia, where SCAI 2022 is taking place this year. At the conference, leading calcium experts will share the 1-year results from the Randomized Disrupt PAD III Trial and 1-year sex specific outcomes with Coronary IVL.
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
Shockwave Breaking News,
IVL Technology,
DISRUPT PAD,
Coronary Cases,
Peripheral Cases,
PAD Applications - BTK,
Peripheral Conferences,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave M5,
Shockwave S4,
PAD Applications - TEVAR,
Coronary IVL - U.S.,
ShockwaveM5+
The presence of calcium can pose significant challenges in achieving optimal procedural outcomes in PAD treatment and can pose as a barrier to the delivery of large bore access devices. Shockwave IVL is shifting the paradigm in the way physicians approach calcium by simplifying procedures in an efficacious and safe manner. Now the next generation of peripheral IVL technology is here: Shockwave M5+! The Shockwave M5+ extends treatment options with the introduction of its new features; faster pulsing, an extended working length and expanded size matrix.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
Based on Shockwave’s recognition on Fast Company’s 2022 list of the World’s Most Innovative Companies in the medical device sector for “bringing good vibrations to heart procedures,” we sat down with Shockwave CEO Doug Godshall for a Q&A to discuss how innovation is fostered at SWAV and why continual innovation is imperative to the future success of the company.
You can also read more about the honor in the company’s press release, in which Doug is quoted saying, “Shockwave Medical was founded with innovation at our core…not only for pioneering revolutionary and proprietary IVL technology, but also for the ways that innovation permeates every aspect of our business. We are continually evolving and transforming how we do things as we seek to astound our customers with life changing products for the treatment of calcified cardiovascular disease.”
Read More
Topics:
Shockwave Behind-the-Scenes,
Coronary IVL,
Peripheral IVL,
IVL Technology,
ChalkTalk Podcast
2021 was Shockwave’s best year yet! Although it brought challenges, with it came immense opportunities which allowed us to grow and exceed expectations. As we push on into 2022, we are excited for what the year will bring but most importantly, for the opportunities to continue to help improve patient outcomes across the globe. But before we get started, let’s review the highlights of last quarter. We released four data releases, including our 1-year results of our Coronary IVL pivotal study at TCT this year, making it a monumental event. We had some exciting peer-reviewed publications come out, enrolled the first patient in the Disrupt BTK II Study, and much more. Read the latest PulsePoint for all the updates!
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
IVL Technology,
Coronary Cases,
Peripheral Cases,
Shockwave C2,
Shockwave M5,
Shockwave S4,
PulsePoint Newsletter,
Coronary IVL - U.S.
Alternative access strategies in TAVI are prone to higher complication rates when compared to transfemoral access. This leads to the question; should physicians tackle difficult transfemoral over alternative access?
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Conferences,
Peripheral Clinical Data
Great news! The Centers for Medicare and Medicaid Services (CMS) has increased payment for peripheral IVL procedures. The increases apply to procedures performed in anatomical locations above the knee in a hospital outpatient setting. The changes go into effect on January 1, 2022.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
In the latest ChalkTalk podcast, we’re going to listen in on a sponsored discussion that took place with TCTMD during TCT21 about new insights on the latest Coronary IVL data that was presented during the meeting with Drs. Ajay Kirtane, Alexandra Lansky, Matthew Price, and Ziad Ali. Hope you enjoy the conversation and for more information on the data, please visit LetsGetCracking.com.
Read More
Topics:
Shockwave Behind-the-Scenes,
Coronary IVL,
Peripheral IVL,
IVL Technology,
ChalkTalk Podcast
Transfemoral access represents the gold standard for TAVI, with TF access showing a significant reduction in complications and mortality in comparison to alternative access strategies, which add additional complexity and risk to the procedure. Despite the wide acceptance that the transfemoral route provides the safest access for patients, the approach can be hindered by calcified iliac arteries inhibiting delivery of large bore devices by restricting the luminal diameter and reducing vessel compliance. If calcium is not treated adequately prior to TAVI delivery, this can lead to complications such as flow limiting dissection, vessel rupture and unsuccessful delivery of the implant.
Read More
Topics:
Peripheral IVL,
Peripheral Cases,
Peripheral Clinical Data
Winter is coming… and fast but before we enter the final home stretch of the year, let’s recount the milestones of the recent quarter in the latest edition of the PulsePoint Newsletter. Shockwave hit the ground running this quarter by bringing on various IVL experts from across the globe to discuss all things calcium on the ChalkTalk Podcast Series. Shockwave also made headlines in CathLab Digest with several physician-authored perspectives about the role of the technology in clinical practice. And it was great to finally get back to live, in-person conferences like VIVA ’21, where the results from the first 752 patients in the Disrupt PAD III Observational Study were presented. Catch up on what you may have missed and don’t forget watch the CalciumMasterclass.com series finale!
Read More
Topics:
Coronary IVL,
IVL Case,
Peripheral IVL,
IVL Technology,
Coronary Cases,
Peripheral Cases,
Shockwave C2,
Shockwave M5,
Shockwave S4,
PulsePoint Newsletter,
Coronary IVL - U.S.
